Changing Adjuvant Breast-Cancer Therapy with a Signal for Prevention
Mené sur 1 918 patientes atteintes d'un cancer du sein HR+ de stade précoce après la ménopause, cet essai de phase III évalue l'intérêt, du point de vue de la survie sans maladie, de prolonger pendant 5 ans un traitement adjuvant à base d'inhibiteur d'aromatase après une période initiale de 5 ans (durée médiane de suivi : 6,3 ans)
Five randomized, full-scale studies have reported that 10 years of adjuvant endocrine therapy is beneficial for postmenopausal women with hormone-receptor–positive breast cancer. However, no prior study has involved more than 5 years of aromatase-inhibitor use or assessed a duration of adjuvant endocrine therapy of more than 10 years. Goss and colleagues now provide results from the MA.17R trial supporting the use of an aromatase inhibitor for 10 years and the use of adjuvant endocrine therapy for even longer total durations. The beneficial effects of increasing disease-free survival, with a favorable toxicity profile for continuing the aromatase inhibitor letrozole for 5 additional years, are reassuring, and the findings have direct application for clinical practice.